US Edition‘Landmark study’ led by UNLV shows new path to treat, prevent autism
- A UNLV-led study led by professor Aukasz Sznajder published on April 21 in Nature Neuroscience discovered a new molecular path linked to autism.
- The study followed observations of overlapping cases of myotonic dystrophy and autism, focusing on changes in the DMPK gene that cause both conditions through gene mis-splicing.
- Researchers found mutated DMPK RNAs absorb healthy proteins, disrupting muscle and brain development, and identified this as a landmark RNA-mediated pathway contributing to autism.
- Brumback said the discovery is important and could facilitate treatments targeting mis-splicing to produce healthy protein versions, while Sultan noted this explains one route among many leading to autism.
- The findings may improve autism diagnosis, prevention, and treatment, especially for children with myotonic dystrophy, despite ongoing debate over autism’s primarily genetic causes versus environmental factors.
23 Articles
23 Articles
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
MIAMI, FLORIDA / ACCESS Newswire / May 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across…
Surviving in the mainstream: Capacity of children with autism spectrum disorders to perform academically and regulate their emotions and behavior at school
This study compares teachers’ perceptions of students with autism spectrum disorders (ASD) to their perceptions of typically developing students with …
Full-Spectrum CBD Drug for Autism Spectrum Disorder Poised for Phase 2 Clinical Trials in the US - Cannabis News World
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioral symptoms associated with autism spectrum disorder (ASD). The post Full-Spectrum CBD Drug for Autism Spectrum Disorder Poised for Phase 2 Clinical Trials in the US appeared first on Business of Cannabis.
Can Genetics Predict Autism Intellectual Disabilities?
A new predictive model combining genetics with developmental milestones may help forecast which autistic children are at risk of developing intellectual disabilities. In a large study of over 5,600 children, researchers were able to correctly predict 10% of such cases and differentiate between low and high-risk groups twice as well as current methods.
Autism, or Autism Spectrum Disorder (ASD), is a neurological and developmental condition that affects how a person interacts with the world, communicates, and experiences things. It's a "spectrum" because autistic people are very diverse, and the condition manifests in many different ways, with varying degrees of intensity.
Coverage Details
Bias Distribution
- 76% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
